论文部分内容阅读
目的探讨ⅢA期非小细胞肺癌新辅助化疗疗效的病理组织学评价与临床评价的差异,研究病理组织学疗效与MRP、p53蛋白表达水平的相关性。方法分析我院73例ⅢA期非小细胞肺癌患者新辅助化疗后的临床与病理资料,并检测其MRP、p53蛋白表达水平。结果73例患者的临床疗效评价有效率为60.27%,病理组织学疗效评价有效率为54.79%,两种评价方法比较差异无统计学意义。MRP、p53蛋白表达水平与新辅助化疗的疗效显著性负相关。结论临床评价与病理组织学评价相结合,使新辅助化疗的疗效评价更为准确。MRP、p53蛋白的表达水平与新辅助化疗的病理组织学疗效具有相关性,可以用来预测化疗疗效,指导临床化疗。
Objective To investigate the difference between the histopathological evaluation and clinical evaluation of neoadjuvant chemotherapy in stage Ⅲ A non-small cell lung cancer and to study the correlation between the curative effect of pathological and MRP and p53 protein expression. Methods The clinical and pathological data of 73 patients with stage ⅢA non-small cell lung cancer after neoadjuvant chemotherapy were analyzed and the MRP and p53 protein expression levels were detected. Results The effective rate of clinical evaluation of 73 patients was 60.27%, and the effective rate of pathological evaluation was 54.79%. There was no significant difference between the two evaluation methods. The expression of MRP and p53 protein was negatively correlated with the efficacy of neoadjuvant chemotherapy. Conclusion The combination of clinical evaluation and histopathological evaluation can make the evaluation of neoadjuvant chemotherapy more accurate. The expression level of MRP and p53 protein is correlated with the curative effect of neoadjuvant chemotherapy, which can be used to predict the effect of chemotherapy and guide clinical chemotherapy.